Inozyme Pharma is developing INZ-701, an enzyme replacement therapy intended to restore plasma pyrophosphate (PPi) and prevent pathological calcification in vasculature, kidneys, and bone. The company has demonstrated preclinical proof of concept for INZ-701 in ENPP1 deficiency disorders (GACI and ARHR2) and is expanding the INZ-701 program to include ABCC6 deficiency (PXE). Inozyme has also added a second research program targeting an undisclosed rare bone disease. The proceeds from the Series A2 will be used to advance INZ-701 through IND-enabling studies and into clinical development, with clinical trials expected to start in 2020. Founded in 2017 and licensed from Yale, Inozyme has raised $116 million in venture capital to date, including the newly announced $67 million Series A2. Inozyme Pharma is developing novel medicines, including a lead enzyme replacement therapy, to treat rare disorders of calcification such as GACI and ARHR2. The company was founded in 2016 with technology licensed from Yale University and is based in Cambridge, Mass. It plans to use the proceeds from its recent financing to advance its lead program into the clinic. Inozyme’s approach targets mineral imbalances that cause over‑calcification of soft tissues and under‑mineralization of bone. The company emphasizes strong foundational intellectual property and a multidisciplinary team focused on underserved pediatric populations. Inozyme has also expanded its leadership and appointed experienced industry veterans to support development and regulatory efforts.

Total raised

$116M

Funding rounds

2

Latest round

Series A

Latest activity

Apr 2019